Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN versus CLINDAMYCIN PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN versus CLINDAMYCIN PHOSPHATE.
CLEOCIN vs CLINDAMYCIN PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation.
Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
150-450 mg orally every 6 hours; 300-600 mg IM or IV every 6-8 hours; maximum 4.8 g/day IV.
600 mg IV every 8 hours or 300-450 mg PO every 6 hours
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 8-12 hours in severe hepatic impairment; dialyzable but not clinically used for Clostridium difficile infection.
Terminal half-life 2-4 hours (prolonged to 8-12 hours in severe hepatic impairment; unchanged in renal failure)
Approximately 10% renal as active drug and metabolites, 90% fecal/biliary via enterohepatic circulation; <1% unchanged in urine.
Renal 10% unchanged, fecal/biliary 90% as metabolites (mostly inactive)
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic